Drugs / PB101
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06075849 | Oct 2023 → Oct 2024 | colorectal cancer, gastric cancer, hepatocellular carcinoma | Panolos Bioscience | Unknown | No outcome recorded |
| Phase 1 | NCT07271446 | Sep 2018 → Aug 2019 | non-small cell lung carcinoma | Precision Biotech Taiwan Corp. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PB101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06075849 ↗ |
| Modality | Cell therapy | “PB101 (autologous NK cell product)” NCT07271446 ↗ |
| Route | Intravenous | “via intravenous infusions” NCT07271446 ↗ |